查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1856248

依治療層級、基因型、給藥途徑、通路和疾病階段分類的肝炎藥物市場－2025-2032年全球預測

Hepatitis Therapeutics Market by Therapeutic Class, Genotype, Route Of Administration, Distribution Channel, Stage Of Disease - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝炎治療市場規模將達到 421.3 億美元，複合年成長率為 4.00%。

關鍵市場統計數據
基準年 2024 307.6億美元
預計年份：2025年 320.2億美元
預測年份 2032 421.3億美元
複合年成長率 (%) 4.00%

本書全面介紹了當前肝炎治療格局，重點闡述了科學進展、臨床需求、就醫障礙和戰略要務之間的交匯點。

肝炎治療正處於一個關鍵的十字路口，持續的科學進步與長期存在的臨床和治療可及性挑戰交織在一起。過去十年，更有效的抗病毒藥物和更完善的臨床方案重塑了治療方法，如今，各相關人員面臨著雙重挑戰：既要將臨床療效轉化為實際療效，又要解決診斷、治療可及性和長期疾病管理方面的差異。臨床醫生和計畫管理者越來越關注如何將新的治療方案整合到能夠應對合併症、合併感染和老齡化患者群體的診療路徑中，而公共衛生系統則強調消除肝炎的目標和廣泛的篩檢舉措。

因此，藥物研發者和醫療保健系統必須應對快速的技術變革、監管審查和不斷變化的支付方期望等複雜環境。諸如直接抗病毒藥物等技術創新正在重新定義某些類型肝炎的治癒預期，而新的治療方法旨在滿足未被滿足的需求，尤其是在慢性乙型肝炎領域，而功能性治癒是人們夢寐以求的治療終點。同時，診斷和治療的銜接策略也在不斷發展，以滿足分散式模式的需求，包括就地檢驗和遠端醫療管理。因此，相關人員必須協調臨床開發、商業策略和政策參與，以確保技術進步能切實改善不同醫療環境下病患的治療效果。

為實現這一目標，多學科合作至關重要：臨床醫生、支付方、製造商和患者權益組織各自貢獻不同的觀點，這些視角結合起來，便可採取行動，加速臨床有效治療方法的推廣應用，並最佳化疾病的長期管理。引言部分概述了影響當今治療方法決策的核心動態，為深入分析變革性變化奠定了基礎，並重點闡述了決定近期科學進展能否轉化為持久公共衛生影響的策略選擇。

深入說明正在塑造肝炎醫學的變革性變化，包括診斷、監管趨勢、長效治療和綜合護理路徑。

近年來，肝炎治療領域發生了翻天覆地的變化，其影響遠不止於藥物的改進，還包括診斷技術的創新、監管體系的現代化以及新型的醫療服務模式。對於某些病毒性肝炎，從傳統的干擾素療法轉向直接抗病毒藥物治療，從根本上改變了臨床預期，使得療程更短、耐受性更好，且病毒學反應的持久性更高。同時，泛基因型治療方案和聯合治療也得到了顯著發展，旨在簡化給藥方案並滿足不同患者群體的需求。這些藥理學上的進步與診斷技術的改進相輔相成，包括即時檢測和快速檢測策略，從而簡化了從篩檢到治療的整個過程。

此外，監管和報銷框架正在調整，在某些司法管轄區優先考慮加快核准、真實世界證據綜合和基於價值的契約，從而加快創新藥物的上市，同時提高臨床和經濟效益的論證標準。同時，長效製劑和標靶治療方法的出現，為面臨依從性障礙或難以獲得每日口服治療的患者提供了潛在的替代方案。遠端醫療和數位化依從性工具正在社區環境中實現遠端醫療的啟動和監測，進一步重塑了治療路徑。

這些趨勢正導致相關人員之間發生根本性的重組：研發組合越來越傾向於聯合療法和乙肝功能治癒方法，診斷開發商專注於多元化和多重檢測，而支付方則更加重視基於結果的合約和人群健康指標。因此，那些能夠將治療研發與可操作的診斷方法和完善的患者支持系統相結合的公司，將更有能力在多元化的醫療保健系統中，將科學進步轉化為公平的臨床結果。

分析2025年關稅調整如何對肝炎藥物供應鏈、生產選擇與籌資策略產生結構性壓力

2025年的貿易政策變化加劇了全球肝炎藥物供應鏈的複雜性，尤其是在原料藥、特殊輔料和最終產品需要跨越多個司法管轄區的情況下。影響原料和配料的關稅調整可能會增加製造商和經銷商的採購成本，並促使他們快速調整籌資策略和庫存管理。這可能促使製造商加快在地化生產、實現供應商多元化，並協商長期採購協議，以降低其受貿易波動的影響。這些變化與物流壓力（例如貨運成本波動和大批量學名藥的運力限制）相互作用，凸顯了供應鏈韌性的重要性。

醫院、零售藥局和線上銷售管道正在透過重新思考採購政策、優先進行供應商風險評估以及探索替代治療方法來應對，以確保醫療服務的連續性。因此，臨床醫生和採購負責人對影響產品供應和交貨時間的上游因素越來越敏感。如果關稅對中間產品的影響大於最終產品，契約製造和原料藥供應商可能會面臨淨利率下降，並將投資轉向利潤率更高的或本地化的生產。隨著各國政府權衡公共衛生因素與更廣泛的貿易目標，衛生部門和貿易負責人的政策因應措施可能會進一步影響這些動態。

歸根究底，關稅變化帶來的累積影響不應僅被視為一次獨立的定價事件，而應被視為推動生產佈局、分銷協議和庫存策略等各個環節進行結構性調整的催化劑。積極了解自身供應鏈風險、進行情境規劃並尋求區域製造策略夥伴關係關係的企業，能夠降低營運風險，並確保病患和醫療服務提供者獲得更可預測的醫療服務。

詳細的細分洞察揭示了治療層級、基因型複雜性、給藥途徑、分銷管道和疾病階段如何影響臨床開發和准入策略。

細分市場層面的動態變化揭示了臨床開發、商業化和病人參與的微妙路徑，這些路徑取決於治療方式、病毒基因型、給藥途徑、分銷管道和疾病階段。依治療層級分類，我們涵蓋聯合治療、直接抗病毒藥物、干擾素和核苷類似物。直接抗病毒藥物進一步細分為Ns3/4A蛋白酶抑制劑、Ns5A抑制劑、Ns5B聚合酵素抑制劑和泛基因型方案。這種治療分類揭示了漸進式創新和模式轉移將發生在哪裡：Ns5A和Ns5B抑制劑對某些肝炎病毒具有較高的治癒率，而泛基因型方案則減少了對基因型特異性診斷的需求，並簡化了治療流程。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 泛基因型直接抗病毒藥物治療C型肝炎患者的最新真實世界療效數據
  • 在服務不足的人群中推廣使用長效注射療法治療慢性B型肝炎
  • 針對慢性B型肝炎患者，開發以宿主為標靶的治療策略，旨在實現功能性治癒。
  • 價格競爭和透過學名藥直接抗病毒藥物的市場滲透來改善藥物可及性
  • 整合遠端醫療平台以最佳化肝炎治療方案的監測和依從性
  • 發展中國家針對戊型肝炎疫情預防的病毒載體疫苗研究取得進展
  • 丁型肝炎免疫治療中查核點抑制劑與抗病毒藥物聯合療法的進展

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按治療層級的肝炎藥物市場

  • 聯合治療
  • 直接作用抗病毒藥物
    • Ns3/4A蛋白酶抑制劑
    • Ns5A抑制劑
    • Ns5B聚合酵素抑制劑
    • 泛基因型方案
  • 干擾素
  • 核苷酸類似物

第9章 依基因型分類的肝炎治療藥物市場

  • 基因型 1
    • 基因型 1A
    • 基因型 1B
  • 基因型 2
  • 基因型 3
  • 基因型 4
  • 基因型 5
  • 基因型 6

第10章 依給藥途徑分類的肝炎治療市場

  • 注射
    • 靜脈
    • 皮下
  • 口服

第11章 肝炎治療市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 肝炎治療藥物市場依疾病階段分類

  • 急性
  • 慢性的

第13章 各地區的肝炎治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 肝炎藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國肝炎治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Sanofi SA
Product Code: MRR-450A0628DE07

The Hepatitis Therapeutics Market is projected to grow by USD 42.13 billion at a CAGR of 4.00% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 30.76 billion
Estimated Year [2025] USD 32.02 billion
Forecast Year [2032] USD 42.13 billion
CAGR (%) 4.00%

A comprehensive introduction framing the current hepatitis therapeutics environment where scientific advances intersect with clinical demand, access barriers, and strategic imperatives

Hepatitis therapeutics stand at a pivotal juncture where sustained scientific progress converges with persistent clinical and access challenges. Over the past decade, the therapeutic landscape has been reshaped by more effective antiviral agents and refined clinical protocols, and stakeholders now face the dual task of translating clinical efficacy into real-world outcomes while addressing disparities in diagnosis, treatment access, and long-term disease management. Clinicians and program managers are increasingly focused on integrating new regimens into care pathways that accommodate comorbidities, coinfections, and an aging patient population, even as public health systems emphasize elimination targets and broader screening initiatives.

Consequently, pharmaceutical developers and health systems must navigate a complex environment of rapid innovation, regulatory scrutiny, and shifting payer expectations. Innovations such as direct-acting antivirals have redefined expectations of cure for certain hepatitis forms, and emerging modalities aim to address unmet needs that remain, particularly in chronic hepatitis B where functional cure remains an aspirational endpoint. Meanwhile, diagnostics and linkage-to-care strategies are evolving to meet the demands of decentralized models, including point-of-care testing and telehealth-enabled management. As a result, stakeholders must align clinical development, commercial strategy, and policy engagement to ensure that technological progress delivers measurable improvements in patient outcomes across diverse care settings.

In this context, multidisciplinary collaboration becomes essential. Clinicians, payers, manufacturers, and patient advocacy groups each bring actionable perspectives that, when coordinated, accelerate adoption of clinically validated therapies and optimize long-term disease control. Accordingly, the introduction outlines the core dynamics shaping therapeutic decision-making today, sets the stage for deeper analysis of transformative shifts, and underscores the strategic choices that will determine whether recent scientific gains translate into durable public health impact.

A detailed exploration of the transformative shifts reshaping hepatitis therapeutics including diagnostics, regulatory momentum, long-acting modalities, and integrated care pathways

Over recent years, the hepatitis therapeutics landscape has undergone transformative shifts that extend beyond incremental drug improvements to encompass diagnostic innovation, regulatory modernization, and new models of care delivery. The transition from legacy interferon regimens toward direct-acting antivirals for certain viral hepatitis types fundamentally altered clinical expectations, enabling shorter, better-tolerated courses and higher sustained virologic responses. In parallel, there has been a pronounced pivot toward pan-genotypic regimens and combination therapies designed to simplify prescribing and broaden applicability across diverse patient populations. These pharmacologic advances have been matched by improvements in diagnostics, including point-of-care assays and reflex testing strategies that streamline screening-to-treatment pathways.

Additionally, regulatory and reimbursement frameworks have adapted to prioritize expedited reviews, real-world evidence integration, and value-based contracting in certain jurisdictions, accelerating the availability of innovative agents while raising the bar for demonstrable clinical and economic benefit. At the same time, the emergence of long-acting formulations and host-targeted approaches offers potential alternatives for patients who face adherence barriers or limited access to daily oral therapies. Telemedicine and digital adherence tools have further reconfigured care pathways, permitting remote initiation and monitoring of therapy in community settings.

These converging trends are producing fundamental realignments across stakeholders: R&D portfolios are increasingly oriented toward combination strategies and HBV functional cure approaches; diagnostic developers focus on decentralization and multiplexing; and payers evaluate outcomes-based agreements and population health metrics. As a result, companies that synchronize therapeutic development with pragmatic diagnostics and robust patient support systems will be better positioned to translate scientific gains into equitable clinical outcomes across heterogeneous healthcare infrastructures.

An analytical review of how tariff adjustments in 2025 have exerted structural pressure on supply chains, production choices, and procurement strategies across hepatitis therapeutics

Trade policy changes in 2025 introduced added complexity into the global supply chain for hepatitis therapeutics, particularly where active pharmaceutical ingredients, specialized excipients, and finished products traverse multiple jurisdictions. Tariff adjustments affecting raw materials and components can increase procurement costs for manufacturers and distributors, prompting rapid reassessment of sourcing strategies and inventory management. In turn, manufacturers may accelerate efforts to localize production, diversify supplier bases, or negotiate longer-term procurement contracts to mitigate exposure to trade volatility. These shifts interact with logistical pressures such as freight cost variability and constrained manufacturing capacity for high-volume generics, elevating the importance of supply chain resilience.

Hospitals, retail pharmacies, and online distribution channels are responding by refining purchasing policies, increasing focus on supplier risk assessments, and exploring alternative therapeutic sourcing to maintain continuity of care. Clinicians and procurement officers are consequently more attuned to the upstream factors that influence product availability and delivery timelines. Where tariffs have affected intermediates more than finished products, contract manufacturers and API suppliers face squeezing margins, which can redirect investment toward higher-margin or regionally anchored manufacturing. Policy responses from health authorities and trade negotiators are likely to shape these dynamics further, as governments weigh public health considerations against broader trade objectives.

Ultimately, the cumulative impact of tariff changes is best understood not as an isolated pricing event but as a catalyst for structural adjustments across manufacturing footprints, distribution agreements, and inventory strategies. Companies that proactively map supply chain exposures, engage in scenario planning, and pursue strategic partnerships for regional manufacturing will reduce operational risk and ensure more predictable access for patients and providers.

In-depth segmentation insights revealing how therapeutic class, genotype complexity, administration routes, distribution channels, and disease stage shape clinical development and access strategies

Segment-level dynamics reveal nuanced pathways for clinical development, commercialization, and patient engagement that depend on therapeutic modality, viral genotype, route of administration, distribution channel, and disease stage. Based on Therapeutic Class, the landscape spans Combination Therapies, Direct Acting Antivirals, Interferons, and Nucleotide Analogues, with Direct Acting Antivirals further subdivided into Ns3/4A Protease Inhibitors, Ns5A Inhibitors, Ns5B Polymerase Inhibitors, and Pan Genotypic Regimens. This therapeutic taxonomy highlights where incremental innovation versus paradigm shifts occur: Ns5A and Ns5B inhibitors have driven high cure rates for certain hepatitis viruses, while pan-genotypic regimens reduce the need for genotype-specific diagnostics and simplify treatment algorithms.

Based on Genotype, development and clinical decision-making account for Genotype 1 through Genotype 6, with Genotype 1 further classified into Genotype 1A and Genotype 1B. Genotype-specific efficacy profiles continue to guide regimen selection in contexts where genotyping remains standard of care, whereas broader use of pan-genotypic options is lowering the clinical and operational friction associated with genotype determination. Based on Route Of Administration, therapies are delivered via Injectable and Oral routes, the Injectable category itself comprising Intravenous and Subcutaneous administration. The rise of long-acting injectables and depot formulations introduces new adherence and delivery considerations, particularly in populations with limited daily medication adherence.

Based on Distribution Channel, therapies reach patients through Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, each presenting distinct procurement, cold-chain, and patient support dynamics. Hospital pharmacies typically manage complex inpatient and specialty outpatient regimens and navigate tendering and formulary processes, while online pharmacies accelerate access but also demand rigorous verification and logistics capabilities. Retail pharmacies serve as critical touchpoints for chronic disease management and patient counseling. Based on Stage Of Disease, treatment pathways differ across Acute and Chronic presentations, with acute cases often emphasizing rapid antiviral initiation and chronic disease management prioritizing long-term monitoring, fibrosis staging, and comorbidity management. Together, these segments form an integrated framework that informs clinical trial design, commercial packaging, stakeholder engagement, and the practicalities of adoption across diverse healthcare environments.

A strategic examination of regional dynamics and how Americas, Europe Middle East & Africa, and Asia-Pacific differences influence clinical priorities, manufacturing, and access

Regional dynamics exert a decisive influence on clinical priorities, regulatory strategy, and supply chain design, and understanding the interplay between disease burden, health system architecture, and manufacturing capacity is essential for global planning. In the Americas, concentrated pockets of high prevalence coexist with advanced regulatory pathways and strong private-sector participation in specialty care; consequently, commercial strategies often emphasize value demonstration, payer negotiation, and integration with harm-reduction and screening programs. Moving across to Europe, Middle East & Africa, heterogeneity increases markedly: regulatory harmonization efforts in parts of Europe coexist with resource-constrained settings in parts of the Middle East and Africa, where decentralizing diagnostics and strengthening primary care linkages are top priorities. In that diverse region, procurement mechanisms and public-private partnerships often determine the feasibility of wide-scale treatment initiatives.

In Asia-Pacific, a combination of high disease prevalence in certain geographies and substantial manufacturing and biotech capacity creates unique opportunities and tensions. Several countries in the region serve as hubs for generic production and active pharmaceutical ingredient manufacturing, supporting both local access and global supply. At the same time, regulatory pathways are diversifying as authorities implement adaptive approval frameworks and local clinical evidence requirements. Across regions, differences in payer models, pricing expectations, and public health priorities require tailored engagement; therefore, strategies that succeed in one geography may need significant adaptation elsewhere. Taken together, these regional insights inform where to prioritize clinical investment, how to structure distribution and patient-support programs, and which regulatory pathways will most efficiently convert innovation into clinical impact.

A synthesis of company strategies and competitive dynamics highlighting how innovators, biotechs, and generics align R&D, partnerships, and manufacturing to deliver therapy access

Companies operating in the hepatitis therapeutics arena are evolving their strategic playbooks to balance near-term delivery with longer-term scientific ambition. Originator firms continue to concentrate on innovation that addresses unmet clinical endpoints, particularly curative strategies for chronic hepatitis B and simplified regimens for diverse hepatitis C genotypes, while smaller biotech companies focus on niche mechanisms, host-targeted approaches, and novel delivery formats. Generic manufacturers play a critical role in expanding access by supplying established regimens at lower cost and by participating in voluntary licensing and contract manufacturing arrangements that scale production for broader distribution.

Strategic partnerships and cross-sector collaborations are increasingly decisive: alliances between therapeutics developers and diagnostic companies aim to couple point-of-care testing with immediate linkage-to-treatment, while co-development agreements with contract manufacturers secure capacity and protect against supply-side disruptions. Additionally, companies are investing in real-world evidence programs and post-marketing surveillance to substantiate long-term safety and effectiveness, which in turn supports reimbursement discussions and formulary inclusion. Commercial strategies are adapting as well, with expanded patient support services, digital adherence platforms, and hub-and-spoke distribution models designed to improve persistence and retention in care. Ultimately, the most successful companies will align scientific differentiation with pragmatic commercialization pathways, integrating manufacturing strategy, regulatory foresight, and stakeholder engagement into cohesive operational plans.

Actionable recommendations for industry leaders focused on supply chain resilience, pan-genotypic strategies, integrated diagnostics, stakeholder partnerships, and real-world evidence generation

Industry leaders must adopt an integrative posture that weaves scientific innovation together with resilient supply chains, pragmatic commercialization, and proactive policy engagement. First, diversifying manufacturing footprints and establishing regional contract manufacturing relationships will mitigate trade-policy exposure and improve responsiveness to local procurement cycles. Second, prioritizing pan-genotypic regimens and treatment simplification reduces diagnostic dependency and accelerates uptake in decentralized care settings, while investments in long-acting and alternative delivery approaches expand options for populations challenged by adherence issues. Third, embedding diagnostics into program design-particularly point-of-care testing and reflex algorithms-shortens the pathway from screening to treatment, improving clinical outcomes and operational efficiency.

Moreover, leaders should pursue strategic collaborations with public health agencies and community organizations to design targeted screening and linkage initiatives that address underdiagnosed populations. They should also expand real-world evidence generation to document long-term benefits, safety, and health-economic impact, thereby strengthening reimbursement negotiations and supporting value-based agreements. Financially, hedging procurement risks and negotiating multi-year supply contracts can stabilize access, while dynamic pricing strategies aligned to regional public health priorities will foster broader uptake. Finally, cultivating digital patient engagement and adherence platforms enhances retention in care and supports remote monitoring, enabling scalable models that integrate clinical efficacy with sustained public health outcomes. These combined actions create a resilient and patient-centric approach that converts innovation into measurable improvements across care pathways.

A transparent mixed-methods research methodology combining stakeholder interviews, literature synthesis, regulatory review, and supply chain scenario testing to ensure robust analysis

The research underpinning this analysis employed a mixed-methods approach designed to triangulate clinical, commercial, and policy perspectives. Primary research included semi-structured interviews with clinicians, procurement specialists, regulatory advisors, and patient advocacy leaders to capture on-the-ground operational realities and strategic priorities. Secondary research comprised comprehensive review of peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and public health reports to synthesize evidence on therapeutic efficacy, safety, and guideline evolution. Data on supply chain structure and manufacturing capacity were drawn from industry reports, trade publications, and publicly disclosed corporate filings to map production footprints and logistics flows.

Analytical methods included qualitative synthesis of stakeholder insights, comparative regulatory pathway analysis, and scenario-based supply chain stress testing to assess vulnerabilities and mitigation strategies. Throughout the process, findings were cross-validated through iterative stakeholder feedback to ensure practical relevance and factual robustness. Limitations include variability in publicly available clinical and procurement data across geographies and the evolving nature of trade policy and regulatory standards, which require continuous monitoring. Nonetheless, the methodology provides a rigorous foundation for strategic decision-making by combining technical clinical appraisal with pragmatic operational analysis and stakeholder-validated perspectives.

A concise conclusion synthesizing scientific advances, operational imperatives, and the strategic alignment required to convert therapeutic innovation into sustained public health impact

The hepatitis therapeutics landscape today reflects both unprecedented therapeutic progress and enduring operational complexities that must be addressed to realize broad public health gains. Scientific advances have expanded the therapeutic toolkit, enabling higher cure rates and more tolerable regimens, yet achieving equitable access and sustained disease control requires coordinated action across diagnostics, manufacturing, reimbursement, and care delivery systems. Regional variability in regulatory frameworks, manufacturing capacity, and health system funding means that strategies must be tailored rather than transplanted wholesale from one geography to another. Therefore, success will come to organizations that integrate clinical differentiation with pragmatic pathways to patient access.

In closing, stakeholders should view the current moment as an opportunity to invest in durable solutions: simplify treatment algorithms where clinically appropriate, strengthen supply chain resilience, embed diagnostics into treatment pathways, and generate the real-world evidence needed to support value-based models. By aligning scientific ambition with operational rigor and collaborative partnerships, the sector can convert recent therapeutic breakthroughs into sustainable improvements in patient outcomes and public health impact. This strategic synthesis should guide near-term priorities and long-term planning for organizations committed to advancing hepatitis care across diverse global contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging real-world efficacy data on pan-genotypic direct-acting antivirals in treating hepatitis C patients
  • 5.2. Adoption of long-acting injectable therapies for chronic hepatitis B management in underserved populations
  • 5.3. Development of host-targeted therapeutic strategies aiming for functional cure in chronic hepatitis B patients
  • 5.4. Increased market penetration of generic direct-acting antivirals driving price competition and access improvements
  • 5.5. Integration of telemedicine platforms to optimize monitoring and adherence in hepatitis treatment protocols
  • 5.6. Advancements in viral vector vaccine research targeting hepatitis E for outbreak prevention in developing regions
  • 5.7. Progress in immunotherapy regimens combining checkpoint inhibitors with antivirals for hepatitis D coinfection

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hepatitis Therapeutics Market, by Therapeutic Class

  • 8.1. Combination Therapies
  • 8.2. Direct Acting Antivirals
    • 8.2.1. Ns3/4A Protease Inhibitors
    • 8.2.2. Ns5A Inhibitors
    • 8.2.3. Ns5B Polymerase Inhibitors
    • 8.2.4. Pan Genotypic Regimens
  • 8.3. Interferons
  • 8.4. Nucleotide Analogues

9. Hepatitis Therapeutics Market, by Genotype

  • 9.1. Genotype 1
    • 9.1.1. Genotype 1A
    • 9.1.2. Genotype 1B
  • 9.2. Genotype 2
  • 9.3. Genotype 3
  • 9.4. Genotype 4
  • 9.5. Genotype 5
  • 9.6. Genotype 6

10. Hepatitis Therapeutics Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intravenous
    • 10.1.2. Subcutaneous
  • 10.2. Oral

11. Hepatitis Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Hepatitis Therapeutics Market, by Stage Of Disease

  • 12.1. Acute
  • 12.2. Chronic

13. Hepatitis Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hepatitis Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hepatitis Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Gilead Sciences, Inc.
    • 16.3.2. AbbVie Inc.
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. Bristol-Myers Squibb Company
    • 16.3.5. Johnson & Johnson
    • 16.3.6. F. Hoffmann-La Roche Ltd
    • 16.3.7. Novartis AG
    • 16.3.8. Pfizer Inc.
    • 16.3.9. GlaxoSmithKline plc
    • 16.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEPATITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DI